SUMATRIPTAN IN ACUTE MIGRAINE - PHARMACOLOGY AND REVIEW OF WORLD EXPERIENCE

被引:33
作者
PEROUTKA, SJ
机构
[1] Department of Neurology, Stanford University Medical Center, Stanford, California, 94305-5235
来源
HEADACHE | 1990年 / 30卷
关键词
D O I
10.1111/j.1526-4610.1990.hed30s2554.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
SYNOPSIS The introduction of sumatriptan, a novel abortive anti‐migraine agent, has generated a significant amount of preclinical and clinical interest during the past few years. At the scientific level, sumatriptan is unique in terms of its selective pharmacological properties. The effects of sumatriptan in various experimental paradigms have led to new insights into the pathophysiology of migraine. At the clinical level, sumatriptan appears to be an effective abortive anti‐migraine agent with minimal side effects. Its ability to decrease, rather than exacerbate, the nausea and vomiting of migraine appears to be an important advance in the treatment of migraine. Copyright © 1990, Wiley Blackwell. All rights reserved
引用
收藏
页码:554 / 560
页数:7
相关论文
共 43 条
[1]  
BAAR HA, 1989, CEPHALALGIA, V9, P83
[2]  
BRAND J, 1987, CEPHALALGIA S6, V7, P402
[3]  
BRION N, 1989, CEPHALALGIA, V9, P79
[4]   THE ANTIMIGRAINE DRUG, SUMATRIPTAN (GR43175), SELECTIVELY BLOCKS NEUROGENIC PLASMA EXTRAVASATION FROM BLOOD-VESSELS IN DURA MATER [J].
BUZZI, MG ;
MOSKOWITZ, MA .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 99 (01) :202-206
[5]  
BYER J, 1989, CEPHALALGIA S10, V9, P349
[6]  
DAHLOF C, 1989, CEPHALALGIA S10, V9, P351
[7]  
DOENICKE A, 1988, LANCET, V1, P1309
[8]  
DOENICKE A, 1989, CEPHALALGIA, V9, P89
[9]  
DOENICKE A, 1987, CEPHALALGIA, V7, P438
[10]  
FENIUK W, 1987, British Journal of Pharmacology, V92, p756P